+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07777211

Evaluating Safety, Tolerability, and Preliminary Efficacy of GKL-006 Injection with Chemotherapy in Advanced Pancreatic Cancer

Led by Beijing Gene Key Life Technology Co., Ltd · Updated on 2026-11-04

52

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of GKL-006 injection combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer, specifically ductal adenocarcinoma. This Phase IIIa study is designed to assess how well patients tolerate the treatment, its safety, and initial signs of how well it works. The study also investigates pharmacokinetic and pharmacodynamic characteristics of the treatment. Participants will receive GKL-006 injections every two weeks at low or high doses during Phase I, progressing to a recommended dose in Phase II. All participants also receive the chemotherapy regimen of nab-paclitaxel and gemcitabine intravenously according to the study protocol. The study includes multiple groups low-dose and high-dose GKL-006 with chemotherapy, a Phase II investigational arm with selected GKL-006 dose plus chemotherapy, and a control group receiving chemotherapy alone. Throughout the study, participants will be monitored for safety and treatment effects up to 18 months, including assessments of disease progression, survival, and quality of life using standardized questionnaires. Researchers will also measure immune cell responses, tumor markers, and adverse events. The involvement includes regular evaluations, laboratory tests, and imaging to track disease status and treatment impact over time.

CONDITIONS

Brief Title

A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

Research Team

C

Clinical trial ethics committee subject reception

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here